Schedule 13G ownership disclosure
Kymera Therapeutics Inc
Security class unavailable · CUSIP: 501575104
Event date: 2022-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 5,066,925
- Percent of class
- 9.2000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001839882-23-003764
- Form type
- SC 13G
- Filer
- Atlas Venture Fund X, L.P.
- CIK
- CIK 1628098
- Filed
- Feb 14, 2023
- Reporting period
- Dec 31, 2022
- Description
- Schedule 13G beneficial ownership